Pharmaceutical manufacturers of Dronabinol

Catalent is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad, deep-scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred Contract Development and Manufacturing Organization (CDMO) partner for personalized medicines, blockbuster drugs and consumer health brand extensions. Catalent helps accelerate over 1,000 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply over 80 billion doses of nearly 8,000 products annually. Its rapidly growing expert workforce exceeds 18,000, including more than 3,000 scientists and technicians. Headquartered in Somerset, New Jersey, Catalent, Inc. (NYSE:CTLT), is in S&P 500® company, and generated nearly $5 billion in revenue in its 2022 fiscal year.

MNK’s Specialty Generics division provides a wide variety of high-quality generic medications, focusing on pain relief, addiction treatment, and ADHD, as well as a comprehensive range of active pharmaceutical ingredients (APIs), such as acetaminophen/paracetamol, DEA scheduled compounds, and stearates. We run the largest API facility in the United States. Discover the range of excipients available from Mallinckrodt Pharmaceuticals for use in pharmaceutical drug delivery systems (DDS).

Transo-Pharm, a fully authorized and accredited distributor, specializes in pharmaceutical components for the medical and veterinary sectors. It provides assistance to customers throughout the entire API life cycle, from product innovation to sales. Transo-Pharm acts as a sourcing and regulatory marketing representative for API producers. It assists customers in establishing DMFs and offers GMP advisory services. With a dedicated regulatory division, a storage facility, proprietary IPs for API procedures, and collaborations with research facilities, Transo-Pharm offers a broad array of services. It operates from its establishments in Shanghai, Hong Kong, Singapore, and the United States.

Purisys LLC, a division of Noramco LLC, provides a wide range of production and personnel resources for the creation, production, and maintenance of pharmaceutical APIs and other chemical synthesis projects. The primary research and development facility and production site in Athens, GA (17,000 square feet) possesses extensive expertise in intricate high-barrier custom synthetic chemistry and the manufacturing of pharmaceutical APIs, along with comprehensive knowledge in controlled substances. Purisys offers 4 validated commercial, ICH Q7/EU GMP compliant APIs and leads globally in the manufacture of pharmaceutical-grade cannabinoids.

THC Pharm GmbH is engaged in groundbreaking work in the advancement of pharmaceutical treatment methods for critically ill and medically complex patients. A primary focus is on supplying the prescription substances dronabinol and cannabidiol, which are categorized as cannabinoids, for supportive therapy. This is particularly important as the availability of approved ready-to-use medicinal products is often challenging, especially for challenging pediatric and palliative patient cohorts.

Benuvia Therapeutics Inc. focuses on financing and advancing low-risk assets with high clinical significance to enhance the quality of life for patients suffering from rare and underserved ailments. We are looking for collaborations to aid in the late-stage development and commercialization of our product pipeline. In the U.S., Benuvia markets SYNDROS®, an FDA-approved cannabinoid medication. Additionally, we operate a cutting-edge Research & Development and cGMP manufacturing facility through our affiliate, Benuvia Manufacturing.